-
摘要: 外科手术是低中危的二尖瓣反流(MR)患者的黄金标准治疗方法，但许多患者因围术期风险过大禁忌外科手术。近年来，MR在高龄高危手术风险患者中的患病率越来越高，多项临床研究证实了经导管二尖瓣缘对缘修复为MR最重要、最广泛的治疗手段，具有较高的安全性、有效性以及耐久性。目前许多其他经导管二尖瓣修复技术正在研发中，并处于研究阶段，期待越来越多的经导管二尖瓣修复技术问世，给治疗MR带来新的选择。
-
关键词:
- 二尖瓣反流 /
- 经导管缘到缘二尖瓣修复 /
- 可用装置 /
- 局限性
Abstract: Although surgery is the gold standard treatment for low-to-moderate-risk mitral regurgitation (MR) patients, surgery is contraindicated in many patients due to excessive perioperative risk. In recent years, the prevalence of MR in elderly patients with high risk of surgery has been increasing. Several clinical studies have confirmed that transcatheter mitral valve edge-to-edge repair (TEER) is the most important and extensive treatment for MR with high safety, efficacy and durability. Many other transcatheter mitral valve repair techniques are currently under development and are in the research stage, and it is expected that more and more transcatheter mitral valve repair techniques will come out, bringing new options for the treatment of MR. -
-
[1] Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study[J]. Lancet, 2006, 368(9540): 1005-1011. doi: 10.1016/S0140-6736(06)69208-8
[2] Goode D, Dhaliwal R, Mohammadi H. Transcatheter mitral valve replacement: state of the art[J]. Cardiovasc Eng Technol, 2020, 11(3): 229-253. doi: 10.1007/s13239-020-00460-4
[3] Dziadzko V, Dziadzko M, Medina-Inojosa JR, et al. Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome[J]. Eur Heart J, 2019, 40(27): 2194-2202. doi: 10.1093/eurheartj/ehz314
[4] Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force On Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2017, 70: 252-289. doi: 10.1016/j.jacc.2017.03.011
[5] Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Thorac Cardiovasc Surg, 2014, 148: e1-e132. doi: 10.1016/j.jtcvs.2014.05.014
[6] Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?[J]. Eur Heart J, 2007, 28: 1358-1365. doi: 10.1093/eurheartj/ehm001
[7] Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the MitralClip system: safety and midterm durability in the initial EVEREST(Endovascular Valve Edge-to-Edge Repair Study)cohort[J]. J Am Coll Cardiol, 2009, 54(8): 686-694. doi: 10.1016/j.jacc.2009.03.077
[8] Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST Ⅱ(Endovascular Valve Edge-to-Edge Repair)High Risk Study[J]. J Am Coll Cardiol, 2012, 59: 130-139. doi: 10.1016/j.jacc.2011.08.067
[9] Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST Ⅱ[J]. J Am Coll Cardiol, 2015, 66: 2844-2854. doi: 10.1016/j.jacc.2015.10.018
[10] Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure[J]. N Engl J Med, 2018, 379(24): 2307-2318. doi: 10.1056/NEJMoa1806640
[11] Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation[J]. N Engl J Med, 2018, 379(24): 2297-2306. doi: 10.1056/NEJMoa1805374
[12] Praz F, Spargias K, Chrissoheris M, et al. Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study[J]. Lancet, 2017, 390(10096): 773-780. doi: 10.1016/S0140-6736(17)31600-8
[13] Lim DS, Kar S, Spargias K, et al. Transcatheter valve repair for patients with mitral regurgitation: 30-day results of the CLASP study[J]. JACC Cardiovasc Interv, 2019, 12(14): 1369-1378. doi: 10.1016/j.jcin.2019.04.034
[14] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2021, 77: 450-500.
[15] Davidson LJ, Davidson CJ. Transcatheter treatment of valvular heart disease: a review[J]. JAMA, 2021, 325(24): 2480-2494. doi: 10.1001/jama.2021.2133
[16] Ge Z, Pan W, Zhou D, et al. Effect of a novel transcatheter edge-to-edge repair device on the three-dimensional geometry of mitral valve in degenerative mitral regurgitation[J]. Catheter Cardiovasc Interv, 2020, 97(1): 177-185.
[17] 潘文志, 龙愉良, 周达新, 等. 经导管二尖瓣缘对缘修复(TEER)的过去、现在和未来[J]. 中国胸心血管外科临床杂志, 2021, 28(12): 1409-1413. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYX202112003.htm
[18] Ben-Shosha J, Overtchook P, Buithieu J, et al. Predictors of outcomes following transcatheter edge-to-edge mitral valve repair[J]. JACC Cardiovasc Interv, 2020, 13(15): 1733-1748. doi: 10.1016/j.jcin.2020.03.025
[19] Sudarsky D, Kusniec F, Grosman-Rimon L, et al. Immediate post-procedural and discharge assessment of mitral valve function following transcatheter edge-to-edge mitral valve repair: correlation and association with outcomes[J]. J Clin Med, 2021, 10(22): 5448. doi: 10.3390/jcm10225448
-
下载:
图(2)
计量
- 文章访问数: 811
- PDF下载数: 474
- 施引文献: 0